A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6300 participants.
Also called NCT01958957
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 6,300 participants
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
- Registry
-
NCT01958957
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01958957. Allocation not applicable; no masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2014-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Ginkgolides Meglumine Injection
- Lead sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
- Collaborator
- Beijing Bionovo Medicine Development Co., Ltd.
Record details
- Record id
cardio:ct-nct01958957- Content hash
338e0e9aa3db2437d80787f3f5be67d67964e4d5d7937871b64a5d75617b206f